NATCO launches additional strengths for generic version of Revlimid in US

Last edition

Home › News › Drug Discovery & Development

NATCO launches additional strengths for generic version of Revlimid in US

NATCO Pharma has announced the launch of additional strengths for the generic version of Revlimid (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the US, through its marketing partner Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries.

With this launch the companies made available all the strengths of lenalidomide in the US market. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

Read more on:
NATCO Pharma Revlimid

More news about: drug discovery & development | Published by Sudeep Soparkar | March - 11 - 2023 | 596

Last news about this category

Glenmark Pharmaceuticals Inc., USA Launches Clindamycin Phosphate Foam, 1 percent

Hoth Therapeutics Collaborates with OnTargetx R&D Inc. to Advance Research for its Cancer-Fighting Therapeutic 'HT-KIT'

Cosmo and Glenmark Receive UK MHRA Approval of Winlevi for Treatment of Acne

Jupiter Neurosciences Signs JOTROL Manufacturing Agreement with Catalent

Akums Combines Two Potent Diabetes Medicines for Enhanced Treatment Efficacy

Kenox Pharmaceuticals Enhances Capabilities to Boost Drug Development

FDA Grants Priority Review to Merck's Application for 'WELIREG'

Glenmark Pharmaceuticals Unveils Generic Anticoagulant Injectable Emulsion

Catalyst Pharmaceuticals Announces Launch of FIRDAPSE in Japan by DyDo

Absci and Owkin Partner to Propel Generative AI in Drug Discovery

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy